Pérez Del Río Eduardo, Santos Fabião, Rodriguez Rodriguez Xavier, Martínez-Miguel Marc, Roca-Pinilla Ramon, Arís Anna, Garcia-Fruitós Elena, Veciana Jaume, Spatz Joachim P, Ratera Imma, Guasch Judith
Institute of Materials Science of Barcelona (ICMAB-CSIC), Campus UAB, Bellaterra, 08193, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Campus UAB, Bellaterra, 08193, Spain.
Institute of Materials Science of Barcelona (ICMAB-CSIC), Campus UAB, Bellaterra, 08193, Spain.
Biomaterials. 2020 Nov;259:120313. doi: 10.1016/j.biomaterials.2020.120313. Epub 2020 Aug 13.
Recent achievements in the field of immunotherapy, such as the development of engineered T cells used in adoptive cell therapy, are introducing more efficient strategies to combat cancer. Nevertheless, there are still many limitations. For example, these T cells are challenging to manufacture, manipulate, and control. Specifically, there are limitations in producing the large amounts of therapeutic T cells needed for these therapies in a short period of time and in an economically viable manner. In this study, three-dimensional (3D) poly(ethylene) glycol (PEG) hydrogels covalently combined with low molecular weight heparin are engineered to resemble the lymph nodes, where T cells reproduce. In these hydrogels, PEG provides the needed structural and mechanical properties, whereas heparin is used as an anchor for the cytokine CCL21, which is present in the lymph nodes, and can affect cell migration and proliferation. The 3D structure of the hydrogel in combination with its loading capacity result in an increased primary human CD4 T cell proliferation compared to the state-of-the-art expansion systems consisting of artificial antigen presenting cells. Thus, we present a new tool for adoptive cell therapy to help achieving the large numbers of cells required for therapy of selected phenotypes targeted against cancer cells, by mimicking the lymph nodes.
免疫疗法领域的最新成果,如过继性细胞疗法中工程化T细胞的开发,正在引入更有效的抗癌策略。然而,仍然存在许多局限性。例如,这些T细胞在制造、操作和控制方面具有挑战性。具体而言,在短时间内以经济可行的方式生产这些疗法所需的大量治疗性T细胞存在局限性。在本研究中,将与低分子量肝素共价结合的三维(3D)聚乙二醇(PEG)水凝胶设计成类似于T细胞繁殖的淋巴结。在这些水凝胶中,PEG提供所需的结构和机械性能,而肝素用作淋巴结中存在的细胞因子CCL21的锚定物,并且可以影响细胞迁移和增殖。与由人工抗原呈递细胞组成的最先进的扩增系统相比,水凝胶的3D结构及其负载能力导致原代人CD4 T细胞增殖增加。因此,我们提出了一种过继性细胞疗法的新工具,通过模拟淋巴结来帮助获得针对癌细胞的选定表型治疗所需的大量细胞。